In rectal cancer, the percentage of CD14+CD16- monocytes was increased in patients with M-positive status, compared to M-negative status (85,66 (70,18-93,7) vs. 81,53 (74,59-86,07), p=0,019), while percentage of CD14-CD16+ monocytes was decreased in M-positive status, compared to M-negative status (5,98 (3,19-8,08) vs. 6,92 (1,73-13,14), p=0,07) (data not shown). Here, CD14 is linked to rectal cancer.